Loading...
XSHG
600211
Market cap1.90bUSD
Dec 05, Last price  
41.70CNY
1D
-0.43%
1Q
-17.39%
Jan 2017
7.84%
Name

Tibet Rhodiola Pharmaceutical Holding Co

Chart & Performance

D1W1MN
XSHG:600211 chart
P/E
12.78
P/S
4.79
EPS
3.26
Div Yield, %
4.62%
Shrs. gr., 5y
5.24%
Rev. gr., 5y
17.45%
Revenues
2.81b
-10.45%
696,482,195861,841,830823,237,884991,069,9641,109,621,0751,110,729,2681,079,038,0191,221,385,4211,402,221,1591,668,036,0411,382,755,815796,806,691915,625,7171,027,879,2101,256,021,9571,373,105,1052,138,586,5522,554,609,0663,134,328,3502,806,713,000
Net income
1.05b
+31.26%
03,077,27406,486,26419,087,06723,556,57620,514,32930,530,18127,153,18020,979,87091,635,772198,289,475229,645,747215,606,211312,321,254418,095,830208,938,062369,839,847800,913,9811,051,288,000
CFO
995m
-8.07%
18,918,70433,629,555021,457,33717,884,2571,900,16912,090,45256,200,572279,222,0050133,930,272250,204,85991,457,114289,217,375489,592,488428,165,608366,531,412837,377,0381,082,137,896994,791,000
Dividend
Aug 29, 20240.967 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.
IPO date
Jul 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT